Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Robinson, Lisa A.
and
Hammitt, James K.
2013.
Skills of the trade: valuing health risk reductions in benefit-cost analysis.
Journal of Benefit-Cost Analysis,
Vol. 4,
Issue. 1,
p.
107.
Pandya, Chintan
Hashmi, Shahrukh
Khera, Nandita
Gertz, Morie A.
Dispenzieri, Angela
Hogan, William
Siddiqui, Mustaqeem
Noyes, Katia
and
Kumar, Shaji K.
2014.
Cost‐effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.
Clinical Transplantation,
Vol. 28,
Issue. 10,
p.
1084.
Thorat, Teja
Lin, Pei-Jung
and
Neumann, Peter J.
2015.
The State of Cost-Utility Analyses in Asia: A Systematic Review.
Value in Health Regional Issues,
Vol. 6,
Issue. ,
p.
7.
Chambers, James D
Thorat, Teja
Pyo, Junhee
and
Neumann, Peter J
2015.
The lag from FDA approval to published cost-utility evidence.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 15,
Issue. 3,
p.
399.
Neumann, Peter J.
Thorat, Teja
Shi, Jennifer
Saret, Cayla J.
and
Cohen, Joshua T.
2015.
The Changing Face of the Cost-Utility Literature, 1990–2012.
Value in Health,
Vol. 18,
Issue. 2,
p.
271.
Krutilla, Kerry
Good, David H.
and
Graham, John D.
2015.
Uncertainty in the Cost-Effectiveness of Federal Air Quality Regulations.
Journal of Benefit-Cost Analysis,
Vol. 6,
Issue. 1,
p.
66.
Neumann, Peter J.
Thorat, Teja
Zhong, Yue
Anderson, Jordan
Farquhar, Megan
Salem, Mark
Sandberg, Eileen
Saret, Cayla J.
Wilkinson, Colby
Cohen, Joshua T.
and
Speybroeck, Niko
2016.
A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.
PLOS ONE,
Vol. 11,
Issue. 12,
p.
e0168512.
2017.
Diagnosis.
p.
325.
Lavelle, Tara A.
Kent, David M.
Lundquist, Christine M.
Thorat, Teja
Cohen, Joshua T.
Wong, John B.
Olchanski, Natalia
and
Neumann, Peter J.
2018.
Patient Variability Seldom Assessed in Cost-effectiveness Studies.
Medical Decision Making,
Vol. 38,
Issue. 4,
p.
487.
Thorat, Teja
Neumann, Peter J.
and
Chambers, James D.
2018.
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Journal of Managed Care & Specialty Pharmacy,
Vol. 24,
Issue. 7,
p.
632.
Olchanski, Natalia
Hansen, Ryan N
Pope, Elle
D’Cruz, Brittany
Fergie, Jaime
Goldstein, Mitchell
Krilov, Leonard R
McLaurin, Kimmie K
Nabrit-Stephens, Barbara
Oster, Gerald
Schaecher, Kenneth
Shaya, Fadia T
Neumann, Peter J
and
Sullivan, Sean D
2018.
Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.
Open Forum Infectious Diseases,
Vol. 5,
Issue. 3,
Lavelle, Tara A.
D’Cruz, Brittany N.
Mohit, Babak
Ungar, Wendy J.
Prosser, Lisa A.
Tsiplova, Kate
Vera-Llonch, Montserrat
and
Lin, Pei-Jung
2019.
Family Spillover Effects in Pediatric Cost-Utility Analyses.
Applied Health Economics and Health Policy,
Vol. 17,
Issue. 2,
p.
163.
Herrera-Araujo, Daniel
Hammitt, James K.
and
Rheinberger, Christoph M.
2020.
Theoretical bounds on the value of improved health.
Journal of Health Economics,
Vol. 72,
Issue. ,
p.
102341.
Aranda-Reneo, Isaac
Rodríguez-Sánchez, Beatriz
Peña-Longobardo, Luz María
Oliva-Moreno, Juan
and
López-Bastida, Julio
2021.
Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis.
Value in Health,
Vol. 24,
Issue. 3,
p.
431.
Rodriguez-Sanchez, Beatriz
Aranda-Reneo, Isaac
Oliva-Moreno, Juan
and
Lopez-Bastida, Julio
2021.
Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.
ClinicoEconomics and Outcomes Research,
Vol. Volume 13,
Issue. ,
p.
307.
Sinha, Pranay
and
Linas, Benjamin P
2021.
Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.
Clinical Infectious Diseases,
Vol. 73,
Issue. 11,
p.
2116.
Sharma, Deepshikha
Aggarwal, Arun Kumar
Downey, Laura E.
and
Prinja, Shankar
2021.
National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison.
PharmacoEconomics - Open,
Vol. 5,
Issue. 3,
p.
349.
Ramkumar, Dipak B.
Kelly, Sean P.
Ramkumar, Niveditta
Gyftopoulos, Soterios
Raskin, Kevin A.
Lozano‐Calderon, Santiago A.
and
Chang, Connie Y.
2021.
Adjunct diagnostic strategies in improving diagnostic yields in image‐guided biopsies of musculoskeletal neoplasms—A cost‐effectiveness analysis.
Journal of Surgical Oncology,
Vol. 124,
Issue. 8,
p.
1499.
Pandya, Ankur
Yu, Yuan-Jui
Ge, Yin
Nagel, Eike
Kwong, Raymond Y.
Bakar, Rafidah Abu
Grizzard, John D.
Merkler, Alexander E.
Ntusi, Ntobeko
Petersen, Steffen E.
Rashedi, Nina
Schwitter, Juerg
Selvanayagam, Joseph B.
White, James A.
Carr, James
Raman, Subha V.
Simonetti, Orlando P.
Bucciarelli-Ducci, Chiara
Sierra-Galan, Lilia M.
Ferrari, Victor A.
Bhatia, Mona
and
Kelle, Sebastian
2022.
Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease.
Journal of Cardiovascular Magnetic Resonance,
Vol. 24,
Issue. 1,
p.
1.
Janko, Mark M.
Joffe, Jonah
Michael, Danielle
Earl, Lauren
Rosettie, Katherine L.
Sparks, Gianna W.
Albertson, Samuel B.
Compton, Kelly
Pedroza Velandia, Paola
Stafford, Lauryn
Zheng, Peng
Aravkin, Aleksandr
Kyu, Hmwe H.
Murray, Christopher J.L.
and
Weaver, Marcia R.
2022.
Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
Vaccine,
Vol. 40,
Issue. 28,
p.
3903.